Source link : https://www.newshealth.biz/health-news/stand-alone-adjuvant-immunotherapy-for-early-tnbc/

The role of adjuvant immunotherapy in triple-negative breast cancer (TNBC) remains uncertain. Standard therapy for TNBC includes neoadjuvant pembrolizumab  with chemotherapy followed by pembrolizumab, with or without chemotherapy, after surgery.  One lingering uncertainty has been whether continuing immunotherapy after surgery provides any survival benefit (see previous story).  But there’s another question oncologists continue to wrestle […]

Author : News Health

Publish date : 2024-11-22 12:25:30

Copyright for syndicated content belongs to the linked Source.

Exit mobile version